BioCryst Pharmaceuticals BCRX Stock-Based Comp
Stock-Based Comp at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's stock-based comp?
- BioCryst Pharmaceuticals (BCRX) reported stock-based comp of $16.03M in Q1 2026.
- How has BioCryst Pharmaceuticals's stock-based comp changed year-over-year?
- BioCryst Pharmaceuticals's stock-based comp decreased by 25.0% year-over-year, from $21.37M to $16.03M.
- What is the long-term trend for BioCryst Pharmaceuticals's stock-based comp?
- Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's stock-based comp has grown at a 25.2% compound annual growth rate (CAGR), from $34.64M to $85.07M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.